ASX:NOX Noxopharm (NOX) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free NOX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.23 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Noxopharm alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Noxopharm Stock (ASX:NOX)Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.Read More Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now NOX Stock News HeadlinesApril 20, 2024 | nz.finance.yahoo.comNoxopharm Limited (NOX.AX)April 4, 2024 | au.investing.comFIVE at FIVE AU: ASX up as gold ralliesApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 28, 2024 | msn.comASX Small Caps Lunch Wrap: Who’s thrown a giant sexy spanner in the works this week?February 17, 2024 | wsj.comGenetic Technologies Ltd. ADRFebruary 12, 2024 | au.investing.comThe morning catch up: ASX set to rise; Wall Street mixed as investors await inflation dataFebruary 12, 2024 | au.investing.comNoxopharm extends strategic partnership with Hudson Institute of Medical ResearchFebruary 6, 2024 | afr.comNoxopharm LimitedApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.January 10, 2024 | proactiveinvestors.comFIVE at FIVE AU: ASX logs strong day; retail figures better than expectedJanuary 1, 2024 | msn.comASX December Winners: The best 50 stocks as optimism pushes markets near record highNovember 15, 2023 | proactiveinvestors.comNoxopharm boosts cash position with A$6 million R&D rebateOctober 17, 2023 | proactiveinvestors.comNoxopharm SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammation, study showsOctober 17, 2023 | msn.comASX Health Stocks: Noxopharm jumps +50pc on mRNA vaccine results; Starpharma +25pc on Phase 2 studyOctober 17, 2023 | proactiveinvestors.comNoxopharm soars as study shows SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammationOctober 12, 2023 | au.investing.comNoxopharm and Hudson Institute collaborate on pioneering mRNA researchOctober 11, 2023 | proactiveinvestors.comNoxopharm talks partnership with Hudson Institute of Medical ResearchOctober 4, 2023 | msn.comClosing Bell: Noxopharm ignores screams as unsuspecting local markets ambushed by hellish bank-tech-comms beastieOctober 4, 2023 | msn.comMarket Highlights: Wall Street cops it on strong jobs but who cares when we’ve got all these lovely ASX lithium leadsOctober 4, 2023 | fool.com.auASX healthcare stock Noxopharm explodes 165% on FDA newsOctober 3, 2023 | proactiveinvestors.com.auNoxopharm granted US orphan drug status for CRO-67 pancreatic cancer therapySeptember 28, 2023 | msn.comASX Health Stocks: Anatara moves rapidly to Stage 2 in Phase 1/2 bowel syndrome trialSeptember 28, 2023 | au.investing.comNoxopharm presents encouraging data on CRO-67 at AACR Pancreatic Cancer conferenceMay 25, 2023 | proactiveinvestors.com.auNoxopharm welcomes preliminary data on Veyonda drug trialMay 22, 2023 | proactiveinvestors.comNoxopharm hails new Sofra™ drug inflammation resultsMay 22, 2023 | proactiveinvestors.com.auNoxopharm welcomes presentation of Sofra™ inflammation technologyMay 18, 2023 | msn.comMarket Highlights: FAANG stocks at one-year high, and will US Fed skip a meeting in June?See More Headlines Receive NOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Noxopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:NOX CUSIPN/A CIKN/A Webwww.noxopharm.com Phone61 2 9144 2223FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.95% Return on Assets-31.32% Debt Debt-to-Equity Ratio0.07 Current Ratio12.81 Quick Ratio8.43 Sales & Book Value Annual Sales$3.88 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow15.42 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares292,240,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.71 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Gisela MautnerCEO, Executive MD & DirectorMr. Shawn Van Boheemen FCPAJ.P., Chief Financial OfficerMs. Jeanette Bell Ph.D.Chief Operating OfficerDr. John Wilkinson B.Sc.Ph.D., Chief Scientific Officer of OncologyDr. Olivier Laczka B.S.M.Sc., Ph.D., Chief Scientific Officer of InflammationMr. David James Franks BEc (Age 54)C.A., F Fin, J.P., Company Secretary More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersFrederick (Fred) BartBought 253,001 shares on 9/14/2023Total: $9,108.04 ($0.04/share)Frederick (Fred) BartSold 3,080,189 sharesTotal: $169,410.40 ($0.06/share)Frederick (Fred) BartBought 500,000 shares on 5/9/2023Total: $21,000.00 ($0.04/share)Frederick (Fred) BartBought 1,000,000 shares on 5/4/2023Total: $50,000.00 ($0.05/share) NOX Stock Analysis - Frequently Asked Questions How were Noxopharm's earnings last quarter? Noxopharm Limited (ASX:NOX) issued its quarterly earnings results on Thursday, February, 21st. The company reported ($0.04) earnings per share (EPS) for the quarter. What other stocks do shareholders of Noxopharm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Noxopharm investors own include Venture Minerals (VMS), Lincoln Educational Services (LINC) and Immuron (IMRN). This page (ASX:NOX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Noxopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
